{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:13:45Z","timestamp":1790741625570,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1124\/jpet.119.262287","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T23:19:23Z","timestamp":1586474363000},"page":"184-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect"],"prefix":"10.1016","volume":"374","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-2624","authenticated-orcid":false,"given":"Aman P.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail M.","family":"Seigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwni","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Gao-Li","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.262287_bib1","unstructured":"Anthony LKR (2018) Review of the ADC clinical pipeline, in World ADC Summit, Berlin."},{"key":"10.1124\/jpet.119.262287_bib2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1208\/s12248-016-9929-7","article-title":"Preclinical to clinical translation of antibody-drug conjugates using PK\/PD modeling: a retrospective analysis of inotuzumab ozogamicin","volume":"18","author":"Betts","year":"2016","journal-title":"AAPS J"},{"key":"10.1124\/jpet.119.262287_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","article-title":"Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy","volume":"18","author":"Cilliers","year":"2016","journal-title":"AAPS J"},{"key":"10.1124\/jpet.119.262287_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4161\/cc.8.3.7608","article-title":"Does the cell number 10(9) still really fit one gram of tumor tissue?","volume":"8","author":"Del Monte","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.119.262287_bib5","doi-asserted-by":"crossref","first-page":"e30916","DOI":"10.1371\/journal.pone.0030916","article-title":"Dilated thin-walled blood and lymphatic vessels in human endometrium: a potential role for VEGF-D in progestin-induced break-through bleeding","volume":"7","author":"Donoghue","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.262287_bib6","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4155\/bio.15.85","article-title":"Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development","volume":"7","author":"Khot","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1124\/jpet.119.262287_bib7","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","article-title":"Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen","volume":"66","author":"Kovtun","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.119.262287_bib8","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.molpharmaceut.5b00302","article-title":"Antibody-drug conjugates (ADCs): magic bullets at last!","volume":"12","author":"Lambert","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.119.262287_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10928-006-9043-z","article-title":"Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software","volume":"34","author":"Lavielle","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/jpet.119.262287_bib10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/jpet.119.262287_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1124\/jpet.119.262287_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1124\/jpet.119.262287_bib13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1124\/jpet.119.262287_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","article-title":"Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK\/PD model: a case study with brentuximab-vedotin","volume":"39","author":"Shah","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/jpet.119.262287_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1208\/s12248-014-9576-9","article-title":"A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate","volume":"16","author":"Shah","year":"2014","journal-title":"AAPS J"},{"key":"10.1124\/jpet.119.262287_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11020098","article-title":"A cell-level systems PK-PD model to characterize in vivo efficacy of ADCs","volume":"11","author":"Singh","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1124\/jpet.119.262287_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1208\/s12248-014-9690-8","article-title":"Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition","volume":"17","author":"Singh","year":"2015","journal-title":"AAPS J"},{"key":"10.1124\/jpet.119.262287_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1208\/s12248-016-9904-3","article-title":"Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1)","volume":"18","author":"Singh","year":"2016","journal-title":"AAPS J"},{"key":"10.1124\/jpet.119.262287_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1208\/s12248-017-0071-y","article-title":"Application of a PK-PD modeling and simulation-based strategy for clinical translation of antibody-drug conjugates: a case study with trastuzumab emtansine (T-DM1)","volume":"19","author":"Singh","year":"2017","journal-title":"AAPS J"},{"key":"10.1124\/jpet.119.262287_bib20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1124\/dmd.117.076414","article-title":"Measurement and mathematical characterization of cell-level pharmacokinetics of antibody-drug conjugates: a case study with trastuzumab-vc-MMAE","volume":"45","author":"Singh","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.119.262287_bib21","series-title":"Innovations for Next-Generation Antibody-Drug Conjugates Cancer Drug Discovery and Development","article-title":"Utility of PK-PD modeling and simulation to improve decision making for antibody-drug conjugate development","author":"Singh","year":"2018"},{"key":"10.1124\/jpet.119.262287_bib22","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.xphs.2019.01.034","article-title":"A \u201cdual\u201d cell-level systems PK-PD model to characterize the bystander effect of ADC","volume":"108","author":"Singh","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.119.262287_bib23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","article-title":"Quantitative characterization of in vitro bystander effect of antibody-drug conjugates","volume":"43","author":"Singh","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/jpet.119.262287_bib24","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s11095-015-1626-1","article-title":"Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development","volume":"32","author":"Singh","year":"2015","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.119.262287_bib25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.119.262287_bib26","first-page":"57","article-title":"Factors determining antibody distribution in tumors","volume":"29","author":"Thurber","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.119.262287_bib27","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","article-title":"Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates","volume":"26","author":"van Geel","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1124\/jpet.119.262287_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-009-9155-7","article-title":"Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems","volume":"12","author":"Yang","year":"2010","journal-title":"AAPS J"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.262287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:55:04Z","timestamp":1739973304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0022356524257992"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.262287","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.262287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}